Cholangiocarcinoma presenting with hypercalcemia and thrombocytopenia.
Muharrem BattalBünyamin GürbulakOzgür BostanciMüveddet Banu YılmazYasar OzdenkayaOguzhan KaratepePublished in: Case reports in medicine (2014)
Malignant hypercalcemia and thrombocytopenia may result from bone metastasis of cholangiocarcinoma (CC). Our case was 53-year-old man admitted to emergency department with symptoms of anorexia, weight loss, nausea, vomiting, and general fatigue in February 2012. His laboratory findings showed hypercalcemia and thrombocytopenia. CT showed a large multinodular mass in the right lobe and, extending through left lobe of the liver. We considered the diagnosis of hypercalcemia of malignancy with elevated calcium levels and suppressed PTH level with the existence of skeletal bone metastasis and the absence of parathyroid gland pathology. Treatment of hypercalcemia with IV saline, furosemide, and calcitonin improved the patient symptoms. After the 8th day of admission, calcium level, thrombocytopenia, and other symptoms were normalized. Patient was sustained surgically inoperable and transferred to medical oncology department for the purpose of palliative chemotherapy and intended radiotherapy for bone metastasis. Hypercalcemia relapsed 4 weeks after discharge and patient died at the 5th month after admission due to disseminated metastasis. We should be aware of CC with symptomatic hypercalcemia and rarely low platelet count. The correction of hypercalcemia provides symptomatic relief and stability of patients.
Keyphrases
- emergency department
- case report
- weight loss
- bone mineral density
- end stage renal disease
- locally advanced
- palliative care
- healthcare
- newly diagnosed
- computed tomography
- type diabetes
- chronic kidney disease
- early stage
- bariatric surgery
- squamous cell carcinoma
- acute lymphoblastic leukemia
- soft tissue
- magnetic resonance
- chemotherapy induced
- radiation therapy
- physical activity
- rectal cancer
- roux en y gastric bypass
- multiple myeloma
- postmenopausal women
- tertiary care
- peripheral blood
- contrast enhanced
- gestational age
- obese patients
- adverse drug